Literature DB >> 10840994

Impact of type 1 and type 2 diabetes on patterns and costs of drug prescribing: a population-based study.

J M Evans1, T M MacDonald, G P Leese, D A Ruta, A D Morris.   

Abstract

OBJECTIVE: Utilization and costs of prescription drugs were investigated in diabetic and nondiabetic patients. RESEARCH DESIGN AND METHODS: The study was carried out in Tayside, Scotland, U.K. A validated population-based diabetes register was used to identify patients with type 1 and type 2 diabetes, and a database of all prescriptions dispensed in the community was used to investigate drug utilization in 1995.
RESULTS: In a population of 406,526, there were 974 (0.2%) with type 1 diabetes and 6,869 (1.7%) with type 2 diabetes. The mean dispensed prescribing rates for all drugs (excluding antidiabetic medication) were higher across all age-groups for diabetic patients. After adjusting for age, patients with type 1 diabetes were 2.07 times (95% CI 2.03-2.11) more likely and patients with type 2 diabetes were 1.70 times (1.69-1.71) more likely to be dispensed a drug item than people without diabetes. This likelihood was increased in every drug category, even those not directly related to diabetes, and the proportion and cost of drug items dispensed to diabetic patients was therefore higher than expected given the prevalence of diabetes. Upon projecting these results to the U.K. population, it was discovered that nearly 8% of the U.K. drug budget (Pound Sterling 350 million) is accounted for by patients with diabetes (90% of that by patients with type 2 diabetes).
CONCLUSIONS: This study highlights the increased usage and cost of prescription drugs in diabetes, with type 2 diabetes constituting a particular burden. It was discovered that 1.4% of drug usage in the entire population can be accounted for by the increased prescribing rate of diabetic patients compared with that of nondiabetic patients.

Entities:  

Mesh:

Year:  2000        PMID: 10840994     DOI: 10.2337/diacare.23.6.770

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  8 in total

Review 1.  Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.

Authors:  Sophie Beale; Adrian Bagust; Arran T Shearer; Alan Martin; Lisa Hulme
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Ankle fractures do not predict osteoporotic fractures in women with or without diabetes.

Authors:  J M Pritchard; L M Giangregorio; G Ioannidis; A Papaioannou; J D Adachi; W D Leslie
Journal:  Osteoporos Int       Date:  2011-05-12       Impact factor: 4.507

3.  Cumulative cost of prescription medication in outpatients with type 1 diabetes in Finland.

Authors:  R Lithovius; V Harjutsalo; C Forsblom; P H Groop
Journal:  Diabetologia       Date:  2010-12-07       Impact factor: 10.122

4.  Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels.

Authors:  A Melander; P Folino-Gallo; T Walley; U Schwabe; P-H Groop; T Klaukka; A Vallano; J-R Laporte; M R Gallego; M Schiappa; M Røder; J P Kampmann; A de Swaef; M Aberg; N-O Månsson; U Lindblad
Journal:  Diabetologia       Date:  2006-07-25       Impact factor: 10.122

5.  The cost of Type 1 diabetes mellitus in the United Kingdom: a review of cost-of-illness studies.

Authors:  Jen Kruger; Alan Brennan
Journal:  Eur J Health Econ       Date:  2012-10-18

Review 6.  The economics of screening and treatment in type 2 diabetes mellitus.

Authors:  Maria Raikou; Alistair McGuire
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

7.  The impact of diabetes on prescription drug costs: the population-based Turin study.

Authors:  G Bruno; L Karaghiosoff; F Merletti; G Costa; M De Maria; F Panero; O Segre; P Cavallo-Perin; R Gnavi
Journal:  Diabetologia       Date:  2008-03-04       Impact factor: 10.122

8.  Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia.

Authors:  J Reviriego; R Gomis; J P Marañés; W Ricart; P Hudson; J A Sacristán
Journal:  Int J Clin Pract       Date:  2008-05-16       Impact factor: 2.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.